Roy Fleischmann.

Roy Fleischmann, M medical journal .D., Joel Kremer, M.D., John Cush, M.D., Hendrik Schulze-Koops, M.D., Ph.D., Carol A. Connell, Ph.D., John D. Bradley, M.D., David Gruben, Ph.D., Gene V. Wallenstein, Ph.D., Samuel H. Zwillich, M.D., and Keith S. Kanik, M.D. For the ORAL Solo Investigators: Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis Rheumatoid arthritis is normally a chronic autoimmune disease that is seen as a inflammation and destruction of joints. The disease has a major effect on health status and quality of life and imposes a substantial economic burden on sufferers and society.1 Tofacitinib is a novel oral Janus kinase inhibitor that is getting investigated as a targeted immunomodulator and disease-modifying therapy for arthritis rheumatoid.

‘In some instances, it is lifesaving for both baby and the mom absolutely,’ he said. Medical reasons for a C-section include having had a prior cesarean delivery, situations where the baby is not correctly situated in the womb and problems with the infant’s heart function. Still, Caughey believes that way too many women are having their babies delivered by C-section. For the past several years, groups just like the American Congress of Obstetricians and Gynecologists have already been advocating for fewer C-sections, he said. ‘We have motivated doctors to be thoughtful and not do C-sections willy-nilly,’ Caughey noted. Since 2010, the amount of C-sections has leveled off, he said.